CUVRIOR
Clinical safety rating
cautionComprehensive clinical and safety monograph for CUVRIOR (CUVRIOR).
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
| Metabolism | Metabolized mainly by conjugation and oxidation; minor involvement of CYP450 enzymes. |
| Excretion | Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose. |
| Half-life | Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 0.2–0.3 L/kg, indicating distribution largely confined to plasma and extracellular fluid. |
| Bioavailability | Not administered orally due to poor absorption; bioavailability by oral route is negligible. |
| Onset of Action | Intravenous administration: increase in urine copper excretion observed within 1–2 hours. |
| Duration of Action | Urine copper excretion returns to baseline within 24–48 hours; clinical effect on hepatic copper stores may last several days. |
| Molecular Weight | 596.5 |
300 mg subcutaneously once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; clinical studies included a limited number of patients aged ≥65 years, with no overall differences in safety or efficacy observed. |
| 1st trimester | No adequate human data; animal studies show embryo-fetal toxicity at clinically relevant exposures. Contraindicated in pregnancy. |
| 2nd trimester | No adequate human data; teratogenic potential remains. Contraindicated in pregnancy. |
| 3rd trimester | No adequate human data; may cause fetal harm. Contraindicated in pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for CUVRIOR (CUVRIOR).
| Placental transfer | High molecular weight suggests limited placental transfer, but animal studies demonstrate fetal exposure and toxicity. Placental transfer confirmed in animal models. |
| Breastfeeding | Not recommended during breastfeeding. No data on presence in human milk, but due to potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during therapy and for at least 6 months after last dose. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Copper deficiency from aggressive chelation may increase teratogenic risk; therefore, maintaining copper levels within the therapeutic range is critical. First trimester: highest risk for malformations; second and third trimesters: risk of fetal copper deficiency and impaired development if maternal copper is overchelated. |
| Fetal Monitoring | Monitor maternal serum copper and zinc levels regularly (e.g., every 2-4 weeks) to maintain copper in the therapeutic range (typically 20-50 mcg/dL) and avoid deficiency. Monitor for signs of copper deficiency (anemia, leukopenia, bone marrow suppression). Fetal monitoring includes serial ultrasound for growth and anatomy, and consider fetal echocardiography due to potential cardiac effects. Monitor maternal neurological status if indicated. |
| Fertility Effects | Animal studies have shown no impairment of fertility at therapeutic doses. However, copper deficiency from overchelation can impair reproductive function. In humans, no specific fertility studies are available; Wilson disease itself may affect fertility. Adequate copper maintenance is essential for normal reproductive function. |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to trientine or any component of formulation
| Precautions | Monitor for iron deficiency due to copper chelation, May cause lupus-like syndrome, Monitor liver function tests, Use with caution in patients with renal impairment |
| Food/Dietary | Take CUVRIOR on an empty stomach: at least 1 hour before meals or 2 hours after meals. Avoid high-copper foods such as chocolate, nuts, shellfish, liver, mushrooms, and whole grains. Avoid dairy products and milk within 1 hour of dosing as calcium may reduce absorption. Iron supplements and zinc supplements should be taken at least 2 hours apart from CUVRIOR. |
| Clinical Pearls | CUVRIOR (trientine hydrochloride) is a copper-chelating agent used for Wilson disease. Monitor urinary copper excretion and serum free copper (non-ceruloplasmin bound) to guide dosing. Avoid concurrent use with zinc supplements or other chelators due to antagonism. Administer on an empty stomach (1 hour before or 2 hours after meals) and separate from other medications by at least 1 hour. Iron deficiency anemia can occur due to copper depletion; check iron studies periodically. Neurological worsening may occur early in therapy; use lower starting doses in patients with neurological symptoms. |
| Patient Advice | Take CUVRIOR on an empty stomach, at least 1 hour before or 2 hours after meals. · Separate CUVRIOR from other medications, supplements, or antacids by at least 1 hour. · Do not take CUVRIOR with milk, dairy products, or iron supplements. · Report any new or worsening neurological symptoms, such as tremors, difficulty speaking, or trouble walking, to your doctor immediately. · Regular blood tests are required to monitor copper levels and liver function. · Do not stop taking CUVRIOR abruptly; consult your doctor before making any changes. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose. |
Loading safety data…